These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 33669300)
1. Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia. Ries J; Agaimy A; Wehrhan F; Baran C; Bolze S; Danzer E; Frey S; Jantsch J; Möst T; Büttner-Herold M; Wickenhauser C; Kesting M; Weber M Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33669300 [TBL] [Abstract][Full Text] [Related]
2. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. Yagyuu T; Hatakeyama K; Imada M; Kurihara M; Matsusue Y; Yamamoto K; Obayashi C; Kirita T Oral Oncol; 2017 May; 68():36-43. PubMed ID: 28438290 [TBL] [Abstract][Full Text] [Related]
3. Malignant transformation of oral leukoplakia is associated with macrophage polarization. Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Öztürk H; Neubauer K; Wickenhauser C; Kesting M; Ries J J Transl Med; 2020 Jan; 18(1):11. PubMed ID: 31910881 [TBL] [Abstract][Full Text] [Related]
4. Effect of smoking status and programmed death-ligand 1 expression on the microenvironment and malignant transformation of oral leukoplakia: A retrospective cohort study. Yagyuu T; Funayama N; Imada M; Kirita T PLoS One; 2021; 16(4):e0250359. PubMed ID: 33861793 [TBL] [Abstract][Full Text] [Related]
5. Expression of Programmed Death Ligand 1 and Indoleamine 2,3-Dioxygenase in Oral Lichen Planus and Oral Lichenoid Lesions. Kemppainen O; Mathlin A; Pasonen-Seppänen S; Siponen M J Oral Pathol Med; 2024 Nov; 53(10):613-621. PubMed ID: 39327597 [TBL] [Abstract][Full Text] [Related]
6. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907 [TBL] [Abstract][Full Text] [Related]
7. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Greeshma LR; Joseph AP; Sivakumar TT; Raghavan Pillai V; Vijayakumar G Sci Rep; 2023 Dec; 13(1):21698. PubMed ID: 38066025 [TBL] [Abstract][Full Text] [Related]
8. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Preidl R; Neukam FW; Ries J Oncotarget; 2017 Dec; 8(68):112584-112597. PubMed ID: 29348848 [TBL] [Abstract][Full Text] [Related]
10. [Determination of human papillomavirus in oral leukoplakia,oral lichen planus and oral squamous cell carcinoma]. Cao J; Jin JQ; Deng DJ; Liu HW Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Feb; 48(1):84-8. PubMed ID: 26885914 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis. Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile. Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749 [TBL] [Abstract][Full Text] [Related]
13. Chen Z; Chen Q; Li S; Tu S; Chen Q; Wang A Ann Transl Med; 2022 Feb; 10(3):144. PubMed ID: 35284546 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Hanna GJ; Villa A; Mistry N; Jia Y; Quinn CT; Turner MM; Felt KD; Pfaff K; Haddad RI; Uppaluri R; Rodig SJ; Woo SB; Egloff AM; Hodi FS Cancer Res Commun; 2021 Oct; 1(1):30-40. PubMed ID: 36860910 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of MAGE-A expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Ries J; Agaimy A; Vairaktaris E; Kwon Y; Neukam FW; Strassburg LH; Nkenke E Int J Oncol; 2012 Sep; 41(3):1085-93. PubMed ID: 22751922 [TBL] [Abstract][Full Text] [Related]
16. Progressive increase of human papillomavirus carriage rates in potentially malignant and malignant oral disorders with increasing malignant potential. Szarka K; Tar I; Fehér E; Gáll T; Kis A; Tóth ED; Boda R; Márton I; Gergely L Oral Microbiol Immunol; 2009 Aug; 24(4):314-8. PubMed ID: 19572894 [TBL] [Abstract][Full Text] [Related]
17. The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia. Ries J; Vairaktaris E; Agaimy A; Bechtold M; Gorecki P; Neukam FW; Nkenke E Oncol Rep; 2013 Sep; 30(3):1149-56. PubMed ID: 23784518 [TBL] [Abstract][Full Text] [Related]
18. Role of bcl-2 oncoprotein in oral potentially malignant disorders and squamous cell carcinoma: an immunohistochemical study. Sudha VM; Hemavathy S Indian J Dent Res; 2011; 22(4):520-5. PubMed ID: 22124045 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of Bcl-2 and Ki-67 in oral lichen planus and leukoplakia with different degrees of dysplasia. Pigatti FM; Taveira LA; Soares CT Int J Dermatol; 2015 Feb; 54(2):150-5. PubMed ID: 25265990 [TBL] [Abstract][Full Text] [Related]
20. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus]. Luo L; Shu M; Li S; Cai Y Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]